|
Jun 26
|
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 14
|
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet
|
|
Jun 13
|
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
|
|
Jun 13
|
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
|
Jun 12
|
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
|
|
Jun 12
|
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
|
|
Jun 10
|
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
|
|
May 31
|
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
|
|
May 30
|
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
|
|
May 29
|
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
|
|
May 29
|
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
|
|
May 28
|
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
|
|
May 27
|
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
|
|
May 24
|
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
|
|
May 24
|
Analysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This Week
|
|
May 23
|
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
|
|
May 15
|
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
|
|
May 15
|
Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
|
|
May 14
|
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
|